*** Collaboration Announcement *** | |
Do you have a therapeutic idea worthy of funding? | |
|
Curie.Bio is a new model for venture capital (VC) in biotech focused on helping founders launch serious therapeutics companies.
They act as both your drug discovery copilot & seed investor. They help founders avoid critical mistakes and ensure they have the right plan, data, and story to retain ownership and control over their company.
| |  |
The recent success of their first portfolio company, Forward Therapeutics, validates their model. Their copilots helped these founders develop clinic-ready therapies with blockbuster potential using only $8M in <18 months. That enabled the founders to secure $50M for their Series A while retaining significant equity in their company. Curie.Bio closed their 2nd fund last week, bringing their total assets under management to ~$900M. | |
Check out their Founder Guide to learn more about Curie.bio's new VC model. | |
Help us celebrate RNA Day — coming up on August 1st! | | |
|
|
RNA Day — celebrated every year on the day most closely resembling the start codon (AUG) — is an opportunity to recognize all of the incredible accomplishments and triumphs in RNA research.
Here at the University of Michigan Center for RNA Biomedicine we would like you to join in the festivities by sharing your knowledge and excitement about RNA!
| |
|
Share your fun fact or an insightful piece of RNA trivia on Twitter/X or LinkedIn by August 1st, and don't forget to use #umRNAday and tag us using @umichrna.
Several exciting submissions will be featured in the August issue of the
RNA Transcript.
We can't wait to learn from you!
| | |
|
|
"Bridging efficiency and accuracy in computational drug discovery with Multisite ?-Dynamics (MS?D)"
Oral Defense by Luis Cervantes Vasquez (Medicinal Chemistry.
Under the advisement of Charles Brooks III, Ph.D.
Monday, July 24, 2024 | 1 p.m.
East Conference Room, Rackham Building
| | |
|
|
Our members' publications are available through Altmetric.
Queries currently available:
CRISPR, microRNA, molecule, RNA, RNA therapeutics, transcriptome, and translation.
Below are recent highlights.
| | |
|
Mi Y, Burnham KL, Charles PD, Heilig R, Vendrell I, Whalley J, Torrance HD, Antcliffe DB, May SM, Neville MJ, Berridge G, Hutton P, Geoghegan CG, Radhakrishnan J, Nesvizhskii AI, Yu F; GAinS Investigators; Davenport EE, McKechnie S, Davies R, O'Callaghan DJP, Patel P, Del Arroyo AG, Karpe F, Gordon AC, Ackland GL, Hinds CJ, Fischer R, Knight JC. High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response. Sci Transl Med. 2024 Jun 5;16(750):eadh0185. doi: 10.1126/scitranslmed.adh0185. Epub 2024 Jun 5. PMID: 38838133. | | |
|
Wang F, Holmes MJ, Hong HJ, Thaprawat P, Kannan G, Huynh MH, Schultz TL, Licon MH, Lourido S, Dong W, Brito Querido J, Sullivan WJ Jr, O'Leary SE, Carruthers VB. Translation initiation factor eIF1.2 promotes Toxoplasma stage conversion by regulating levels of key differentiation factors. Nat Commun. 2024 May 23;15(1):4385. doi: 10.1038/s41467-024-48685-4. PMID: 38782906; PMCID: PMC11116398. | | |
For complete details on current openings and how to apply for these positions, visit the Recruitment Opportunities page on our website. | | | | |
